Consejo Nacional de Salud

422
36 Mlineritsch G M, Luschin-Ebengreuth G, Kainberger
F, Kässmann H, Piswanger-Sölkner JC, Seifert
M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-
Radisic V, Steger G, Greil R, Marth C, Kubista E,
Samonigg H, Wohlmuth P, Mittlböck M, Jakesz
R; Adjuvant endocrine therapy plus zoledronic
acid in premenopausal women with early-stage
breast cancer: 5-year follow-up of the ABCSG-12
bone-mineral density substudy. Austrian Breast
and Colorectal Cancer Study Group (ABCSG).
37 Zosia Chustecka , Zoledronic Acid Significantly
Reduced Relapse in Early Breast Cancer, June
2008 (Chicago, Illinois), disponible en: http://
www.medscape.com/viewarticle/575394
38 Musto P, Petrucci MT, Bringhen S, Guglielmelli
T, Caravita T, Bongarzoni V, Andriani A, D'Arena
G, Balleari E, Pietrantuono G, Boccadoro M, A
multicenter, randomized clinical trial comparing
zoledronic acid versus observation in patients with
asymptomatic myeloma. Unit of Hematology
and Stem Cell Transplantation, IRCCS-Oncology
Referral Center of Basilicata, Rionero in Vulture.
Disponible en: http://www.ncbi.nlm.nih.gov/
pubmed/ 17145616?ordinalpos=72&itool=Entrez
System2.PEntrez.Pubmed.Pubmed _ResultsPanel.Pubmed_DefaultReport
Panel.Pubmed_RV-
DocSum